Dr. Florian Lordick summed it up perfectly at #ESMO26 👏 💡 Surrogate endpoints like PFS and ORR can help bring treatments to patients earlier, but they don’t always translate into better overall survival. 🙏Regulatory acceptance doesn’t necessarily mean clinical validation. An important distinction in oncology! @kbaskurtt @osutcuoglu

💚 So happy to be featured in ESMO’s #ESMOcommunity video at #ESMO26 🌍 💫 More than science, oncology is about people, friendships, and a shared passion for better cancer care. 🙏 Thank you, @myESMO, for including me in this amazing community! @FLordick28391 @YJanjigianMD @MartinReck2 @FAndreMD @osutcuoglu @uyargalip @kbaskurtt #ESMO2026 #Oncology #CancerResearch #MedicalOncology #CancerCare #GlobalOncology #YoungOncologists #Madrid2026

🎉 Our new study is now published in JCO Global Oncology! 💊🖐️ Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study 🔬 In this prospective, two-center real-world study of 151 patients receiving capecitabine-based therapy, we evaluated prophylactic topical diclofenac for the prevention of clinically significant hand-foot syndrome (HFS). 📊 Grade ≥2 HFS occurred in 16.9% (12/71) with topical diclofenac versus 13.8% (11/80) with active monitoring (OR 1.28; 95% CI, 0.52–3.10; P = .591). 💡 Our findings showed that prophylactic topical diclofenac did not reduce clinically significant HFS or delay its onset in routine clinical practice, adding prospective real-world evidence to this evolving area of supportive oncology. 🙏 Special thanks to our first author, Dr. Orhun Akdoğan(@drOrhunakdogan) and our mentor, Dr. Osman Sütcüoğlu(@osutcuoglu) for their leadership and guidance, and to our entire team(@uyargalip, @kbaskurtt, @yucelbirkadriye) for their valuable contributions. Grateful to be part of this collaboration! 📖 @JCOGO_ASCO | @ASCO 🔗 ascopubs.org/doi/pdf/10.1200… #JCOGlobalOncology #ASCO #Oncology #SupportiveCare #Capecitabine #HandFootSyndrome #RealWorldEvidence @KVanLoonMD @RyanNipp @thenasheffect @IshwariaMD @ASCOPres

🚨 New in International Journal of Cancer! 🎉 🧤Our NEURO-GLOVE Trial shows that a simple, low-cost dual-site compression strategy 🦵 (surgical gloves + compression stockings during paclitaxel infusion) meaningfully reduces chemotherapy-induced peripheral neuropathy (CIPN) in women with gynecologic cancers. 🔹 Grade ≥2 CIPN: 53.9% → 35.5% at Cycle 3 🔹 Benefit sustained out to 6 months 🔹 Hands protected immediately; feet protected later but durably 🔹 Cheap, scalable, ready for clinic tomorrow 🙏Huge congrats to Dr. Kadriye Başkurt (@kbaskurtt) for carrying this from idea to publication, and to our whole team[Dr.Galip Can Uyar (@uyargalip), Dr.Osman Sütcüoğlu (@osutcuoglu)] for the ride. 📖 Başkurt K, Uyar GC, Yeşilbaş E, et al. Limb Compression Therapy and Chemotherapy-Induced Peripheral Neuropathy in Women With Gynecologic Cancers: A Prospective Self-Controlled Study (NEURO-GLOVE Trial). Int J Cancer. 2026. 🔗 doi.org/10.1002/ijc.70601 #Oncology #CIPN #GynecologicCancer #Paclitaxel #SupportiveCare #NEUROGLOVE @CoquardRay @dimeglio_anto @RyanNipp @IshwariaMD @thenasheffect @realbowtiedoc